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Endpoint
Prior
CABG
(N1133)
No prior
CABG
(N17495) HR (95% CI) p
Efficacy
Primary Outcome:
CV Death / MI
(excluding silent) /
Stroke
20.5 (216) 10.1 (1662) 2.06 (1.79, 2.38) .0001
CV
death/MI/stroke in
patients intended
for invasive
management
18.9 (131) 9.3 (1106) 2.03 (1.69, 2.43) .0001
All Cause Death /
MI (excluding
silent) / Stroke
21.4 (225) 10.6 (1741) 2.05 (1.79, 2.36) .0001
Cardiovascular
Death (includes
vascular and
unknown deaths)
7.2 (75) 4.4 (720) 1.61 (1.27, 2.04) .0001
All Cause Death 8.2 (85) 5.0 (820) 1.60 (1.28, 2.00) .0001
Myocardial
Infarction
(excluding silent)
13.8 (144) 5.9 (953) 2.39 (2.01, 2.85) .0001
Any Stent
Thrombosis
(definite, probable
or possible)
3.5 (33) 2.2 (339) 1.48 (1.04, 2.12) 0.0307
Bleeding (study
criteria)
Any major bleeding 8.4 (84) 11.6 (1806) 0.72 (0.58, 0.89) 0.0029
Coronary Procedure
Related Major
Bleeding
5.0 (51) 9.0 (1426) 0.55 (0.42, 0.73) .0001
Non-Coronary
Procedure Related
Major Bleeding
0.2 (2) 0.4 (62) 0.51 (0.12, 2.08) 0.3484
Conclusions: Prior CABG patients represent a high risk cohort for death and recurrent
cardiovascular events but have lower risk for major bleeding. A reduction in ischemic
events without increase in major bleeding occurred with ticagrelor vs. clopidogrel in prior
CABG patients, similar to the results in non-prior CABG patients.
TCT-740
Clinical impact of extended dual antiplatelet therapy after percutaneous
coronary interventions in the drug-eluting stent era: a meta-analysis of
randomized trials
Salvatore Cassese1, Robert Byrne1, Tomohisa Tada1, Lamin King1,
Adnan Kastrati1
1Deutsches Herzzentrum Munich, Munich, Germany
Background: There is still uncertainty regarding the optimal dual antiplatelet therapy
(DAPT) duration after percutaneous coronary interventions (PCI). We evaluate benefits
and risks of extending DAPT after PCI in the drug-eluting stent era.
Methods: We searched electronic databases (Medline, EMBASE, the Cochrane Central
Register of Controlled Trials), relevant websites, reference lists, conference abstracts,
reviews, chapters in books and proceedings of advisory panels for the US Food and Drug
Administration, for randomized controlled trials investigating the clinical impact of
extending DAPT duration in patients undergoing PCI. The primary endpoint was
all-cause death. The secondary endpoints were myocardial infarction (MI), stent throm-
bosis (ST), cerebrovascular accidents (CVA) and Thrombolysis in Myocardial Infarction
(TIMI) major bleeding.
Results: We included four trials which randomized 8,231 patients (50.2%, extended
DAPT duration versus 49.8%, control duration). A total of 8,158 patients (99.1%) were
available for final analyses. Median DAPT duration was 16.8 versus 6.2 months for the
extended DAPT and control groups, respectively. At follow-up (median 16.8 months)
extending DAPT duration did not reduce all-cause death (odds ratio [95% confidence
interval]  1.15 [0.85-1.54], p0.36), MI (0.95 [0.66-1.36], p0.77), ST (0.88 [0.43-
1.81], p0.73) or CVA (1.51 [0.92-2.47], p0.10). Conversely, extended DAPT duration
clearly increased the risk of TIMI major bleeding (2.64 [1.31-5.30], p0.006).
Conclusions: Extending dual antiplatelet therapy duration after percutaneous coronary
interventions increased the risk of bleeding without reducing the incidence of death,
myocardial infarction, stent thrombosis or cerebrovascular accidents.
TCT-741
Impact of clinical presentation on platelet inhibition by ticagrelor compared
to clopidogrel: insights from a single-center cohort of the PLATO trial
Daniel Aradi1, Iva´n Horva´th1, Balint Kittka1, Andra´s Komo´csi2
1Heart Institute, University of Pécs, Pecs, Hungary, 2University of Pécs, Hungary,
Pécs, Hungary
Background: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor
significantly reduced the risk of thrombotic events compared to clopidogrel in patients
with acute coronary syndromes (ACS). We aimed to investigate whether clinical
presentation (STEMI vs. NSTE-ACS) has any interaction with platelet inhibition between
ticagrelor and clopidogrel.
Methods: In a non-prespecified, single-center, pharmacodynamic analysis of the PLATO
randomized, blinded, placebo-controlled trial, platelet inhibition was compared in patients
randomized to clopidogrel (n55) or ticagrelor (n53) at 24-48 hours of receiving
loading doses (LD) and during the maintenance period (7 days) of treatment. Maximal
platelet aggregation (MPA) was measured with light transmission aggregometry using ADP
5 M. P values for interaction between STEMI and NSTE-ACS were calculated regarding
mean MPA and for the odds of high platelet reactivity (HPR, defined as MPA46%).
Results: In 77(71.3%) patients with STEMI and 31(28.7%) with NSTE-ACS, 94 loading
phase and 150 maintenance phase measurements were performed. Both after the LD and
MD, patients on ticagrelor showed significantly lower MPA values compared to
clopidogrel without any interaction between STEMI and NSTE-ACS (p for interaction:
0.33 and 0.28 after LD and MD, respectively; Table 1) In line with these findings, patients
randomized to ticagrelor experienced a huge reduction in the odds for HPR regardless of the
clinical presentation (p for interaction: 1.00 and 0.30 after LD and MD, respectively; Table 1).
Mean difference
in MPA
(ticagrelor-
clopidogrel, %) 95% CI P interaction
After loading dose
STEMI 27.67 34.19; 21.15 0.30
NSTE-ACS 32.85 41.05;24.65
During maintenance
dose
STEMI 15.93 22.01; 9.85 0.28
NSTE-ACS 21.91 30.79;13.03
Odds ratio for
HPR (ticagrelor
vs. clopidogrel) 95% CI
P
interaction
After loading dose
STEMI 0.02 0.00; 0.20 1.00
NSTE-ACS 0.02 0.00; 0.54
During maintenance
dose
STEMI 0.12 0.04; 0.39 0.30
NSTE-ACS 0.02 0.00; 0.44
Conclusions: MPA values and the rate of HPR were largely and significantly reduced in
patients randomized to ticagrelor both after LD and MD, regardless of the clinical
presentation. This post-hoc, single-center, pharmacodynamic analysis of the PLATO trial
suggest no attenuation of platelet inhibition in patients presenting with STEMI compared
to those with NSTE-ACS.
TCT-742
Individual and Regional Variations in Dual Antiplatelet Therapy Dose and
Duration in a Large, Randomized International Trial Comparing Two Drug-
eluting Stents: Results From PROTECT
Laura Mauri1, Gabriel Steg2, Alexis Matteau3, Edoardo Camenzind4,
Eric Boersma5, Pascal Vranckx6, Patrick Serruys5, William O’Neill7, Robert Yeh8,
William Wijns9
1Brigham and Women’s Hospital and Harvard Medical School, Boston,
Massachusetts, 2Hopital Bichat, Paris, France, Paris, France, 3Brigham and
Women’s Hospital, Boston, MA, 4University Hospital of Geneva, Geneva,
Switzerland, 5ThoraxCenter - Erasmus Medical Center, Rotterdam, Netherlands,
6Hartcentre Hasselt, Hasselt, Belgium, 7Leonard M. Miller School of Medicine,
Miami, USA, 8Massachusetts General Hospital, Boston, USA, 9Cardiovascular
Center Aalst, Aalst, Belgium
Background: Twelve months duration of dual antiplatelet therapy (DAPT) after
implantation of a drug-eluting stent (DES) is recommended to decrease risk of stent
thrombosis (ST). Controversies surround the optimal duration of DAPT for reducing risk
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of thrombosis and whether DAPT should be individualized according to stent type or
lesion or patient subsets is unknown. The Patient Related Outcomes with Endeavor versus
Cypher Stenting Trial (PROTECT) was designed and powered to compare long-term
outcomes of safety endpoints such as ST between the Endeavor zotarolimus-eluting stent
(E-ZES) and the Cypher sirolimus-eluting stent (C-SES).
Methods: PROTECT is a prospective, multicenter, randomized trial conducted at 196
sites in 36 countries worldwide in all continents. Patients with up to 4 coronary lesions
amenable for stenting were randomized to receive E-ZES or C-SES. The primary
endpoint is the 3 year rate of ARC-defined definite and probable ST. DAPT with
clopidogrel and aspirin were prescribed at least for 3 months and at physician discretion
for 12 months or longer. Planned and actual duration of DAPT, utilization of aspirin
(ASA) and clopidogrel by region, and aspirin dose (100mg, 100-300 mg, 300mg)
were collected. Multivariate regression analysis will be used to identify predictors for
DAPT duration of 12 months, DAPT compliance, and the relationship of these factors
with the outcomes of ST, myocardial infarction and cardiac death.
Results: PROTECT enrolled 8,800 patients; mean age 62.210.6 years and 76.3% were
male. Overall, 44.7% of patients presented with acute coronary syndromes, 27.2% had
diabetes mellitus, 20.5% prior MI, and 12.5% prior PCI. Almost all were de novo lesions
(98.2%), 46.6% in the left anterior descending artery and 54.8% were B2/C lesions.
Details of DAPT usage (planned and actual duration, ASA dosage) by region, and
according to patient characteristics will be available for presentation.
Conclusions: Analysis of the variation in duration of DAPT across regions and according
to patient characteristics in a real world setting will further our understanding of the
impact of DAPT on stent specific and global cardiovascular outcomes.
TCT-743
Platelet Function Monitoring In Patients With Acute Myocardial Infarction:
Does Time Matter?
Rebecca Torguson1, Gabriel Sardi2, Kimberly Kaneshige3, Shreejana Pokharel3,
Michael Mahmoudi3, Augusto Pichard4, Ron Waksman5
1Washington Hospital center, washington, DC, 2Washington Hospital Center,
Washington Dc, DC, 3Washington Hospital Center, Washington, DC, 4washsington
hospital center, Washington, USA, 5Georgtown University, Washington, DC
Background: Platelet activation plays a critical role in the pathogenesis of acute
myocardial infarction (AMI). This study aimed to determine whether the results of platelet
function assays used to measure response to clopidogrel therapy are similar among
patients with stable CAD and those with AMI undergoing percutaneous coronary
intervention (PCI) both at the index admission and at 30 days’ post admission.
Methods: Sixty patients were prospectively enrolled into either an elective PCI cohort or
an AMI cohort. Patients presenting with an AMI were approached within 24 hours of
presentation and following PCI for participation. Patients underwent platelet function
testing post-PCI and again at 30 days ( 2 weeks) follow up. Tests included vasodilator
stimulated phosphoprotein phosphorylation (VASP) and VerifyNow P2Y12.
Results: The average age of the population was 64.5  11.2 years with no difference
between the elective and AMI groups. Baseline characteristics were similar, with an
overall rate of diabetes of 26.7%, hypertension 78.3%, current smokers 15.0%, prior CAD
35.0%, renal insufficiency 6.7% and the average BMI was 31  7. The AMI group had
higher PRU, percent inhibition, and PRI at the time of PCI as compared to the elective PCI
group. This difference was not sustained at 30 days. The PRU significantly decreased at
30 days compared to the PCI procedure for the AMI group. Similarly, the percent
inhibition and PRI decreased, but did not achieve statistical significance. (Table).
Conclusions: Platelet reactivity is higher at the time of primary PCI (vs. elective PCI)
with AMI presentation. These data support the notion that the platelets become
hypersensitive at the time of AMI and are passivated over time given antiplatelet therapy.
The on-treatment platelet reactivity should be assessed for patients presenting with AMI
to appropriately tailor the antiplatelet regime.
Elective AMI P Value
Index Procedure
PRU 159.13	/ 93.01 202.97	/ 99.85 0.095
Percent Inhibition 45.57	/ 30.03 23.73	/ 29.86 0.008
VASP-PRI 30.40	/ 24.03 52.63	/ 20.02 0.001
Platelet count 196.19	/ 66.86 218.46	/ 63.70 0.201
AST 27.55	/ 24.88 90.92	/ 88.36 0.002
30 Days Follow
Up
PRU 180.00	/ 93.64 189.52	/ 86.86 0.738
Percent Inhibition 38.28	/ 30.00 31.61	/ 26.94 0.459
VASP-PRI 41.79	/ 22.60 47.92	/ 23.76 0.407
Platelet count 235.35	/ 72.56 243.61	/ 50.50 0.673
Index Procedure 30 Days Follow Up P Value (paired)
Elective
PRU 159.13	/ 93.01 180.00	/ 93.64 0.125
Percent Inhibition 45.57	/ 30.03 38.28	/ 30.00 0.445
VASP-PRI 30.40	/ 24.03 41.79	/ 22.60 0.032
Platelet count 196.19	/ 66.86 235.35	/ 72.56 0.009
AMI
PRU 202.97	/ 99.85 189.52	/ 86.86 0.003
Percent Inhibition 23.73	/ 29.86 31.61	/ 26.94 0.195
VASP-PRI 52.63	/ 20.02 47.92	/ 23.76 0.349
Platelet Count 218.46	/ 63.70 243.61	/ 50.50 0.001
TCT-744
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation
Myocardial Infarction Undergoing Primary Percutaneous Coronary
Intervention
Dimitrios Alexopoulos1, Ioanna Xanthopoulou1, Vassilios Gkizas1,
George Kassimis1, Konstantinos Theodoropoulos1, Tsigkas Grigorios1,
Ioannis Chiladakis1, Anastasia Damelou1, George Hahalis1, Periklis Davlouros1
1Patras University Hospital, Patras, Achaia
Background: In patients with ST elevation myocardial infarction (STEMI) undergoing
primary percutaneous coronary intervention (pPCI) ticagrelor 180mg loading dose (LD)
exhibits a delayed onset of action – from what would be predicted based on assessments
in stable patients. Since Cmax for ticagrelor and its main metabolite increases approxi-
mately dose-proportionately, we hypothesized that doubling the ticagrelor LD in patients
with STEMI undergoing pPCI may lead to faster early platelet inhibition.
Methods: This is a prospective, pharmacodynamic study in P2Y12 inhibitor naïve
patients with STEMI (onset of pain12 hours) undergoing pPCI. Patients after informed
consent received 360mg LD of ticagrelor immediately before pPCI. Platelet reactivity
(PR) was assessed with VerifyNow assay in platelet reactivity units (PRU) immediately
before LD (Hour 0) and at 0.5, 1, 2 and Hour 4 after LD.
Results: Data of 24 patients are presented (79.2%men, mean age 54.79.5 years). At
hour 0 mean PR was 226.866.8 PRU. At hour 0.5, 1, 2 and 4 PR was 272.4 (252.0-292.7
95% CIs), 227.3 (190.2-264.4 95%CIs), 134.7 (85.0-184.3 95%CIs) and 56.8(24.1-89.4
95%CIs) respectively. A statistical significant reduction in PR was observed between
Hour 0 and Hour 2, with a mean difference of -89.9 PRU (-15.1 to -164.8 95%CIs,
p0.01). A statistical significant increase in PR was observed between Hour 0 and Hour
0.5, with a mean difference of 47.8 PRU (17.2 to 78.5 95% CIs, p0.001) PR mean
difference between Hour 1-Hour 2 and Hour 2-Hour 4 was also significant (-92.6 PRU,
-159.8 to -25.4 95%CIs, p0.003 and -77.9 PRU, -135.3 to -20.5, p0.004). No major
adverse cardiovascular events or bleeding events observed until discharge.
Conclusions: In P2Y12 inhibitors naïve STEMI patients undergoing pPCI, an initial
delay in the onset of ticagrelor’s antiplatelet action until Hour 1 is observed, despite the
doubling of the loading dose.
TCT-745
Can aspirin / clopidogrel resistance affect on the occurrence of intra-stent
thrombi ?
Junbeom Park1, Byeong-Keuk Kim2, Dong-Ho Shin3, Jung-Sun Kim4,
Young-Guk Ko5, Donghoon Choi6, Myeong-Ki Hong7, Yangsoo Jang2
1Yonsei University Health system, Seoul, Korea, Republic of, 2Yonsei university,
Seoul, Korea, Republic of, 3Yonsei University College of Medicine, Seoul, Korea,
Republic of, 4Severance Cardiovascular Center, Seoul, Korea, Republic of,
5Younsei University, Seoul, Korea, Republic of, 6Severance Hospital, Yonsei
University, Seoul, Korea, Republic of, 7Yonsei Cardiovascular Hospital, Seoul,
South Korea
Background: No data exit regarding the association between aspirin / clopidogrel
resistance and intra-stent thrombi on follow-up optical coherence tomography (OCT)
following drug-eluting stents (DES) implantation. So we measured the presence of
intra-stent thrombi in OCT and aspirin reaction unit (ARU), P2Y12 reaction unit (PRU),
inhibition ratio of PRU in patients with drug eluting stent (DES).
Methods: From our OCT registry, a total of 313 patients treated with DES underwent
follow-up OCT and performed the measurement of aspirin reaction unit (ARU), P2Y12
reaction unit (PRU), inhibition ratio of PRU using VerifyNow (VN) on the same day for
follow-up OCT. Aspirin and clopidogrel resistance were defined as ARU550 and PRU
250, respectively. For assessing whether aspirin / clopidogrel resistance could be related
to intra-stent thrombi on OCT, we divided the patients according to the presence of aspirin
or clopidogrel resistance, and then compared the occurrence of intra-stent thrombi on
OCT between the patients with or without resistance.
Results: Mean OCT follow-up duration of enrolled 313 patients was 195133 days.
According to the presence of aspirin / clopidogrel resistance, there was no significant
difference in the occurrence of intra-stent thrombi on OCT. On the assessment according
to the major risk factors of coronary artery disease, there was also no significant difference
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